Synthesis, DNA-damaging and cytotoxic properties of novel topoisomerase II-directed bisantrene analogues.
G Zagotto, A Oliva, F Guano, E Menta, G Capranico, M Palumbo
Index: Bioorg. Med. Chem. Lett. 8(2) , 121-6, (1998)
Full Text: HTML
Abstract
New bisantrene analogues were synthesized, bearing one or two 4,5-dihydro-1H-imidazol-2-yl hydrazone side chains at positions 1,4 or 9 of the anthracene ring system. A 10-azabioisostere was also prepared. The position of substituents in structurally isomeric drugs modulates topoisomerase II poisoning and specificity, along with cytotoxicity.
Related Compounds
Related Articles:
In vitro effects of bisantrene on fresh clonogenic leukemia cells: a preliminary study on 15 cases.
1990-01-01
[Haematologica 75(6) , 527-31, (1990)]
Phase II trial of Bisantrene for metastatic melanoma: an Illinois cancer council study.
1991-01-01
[Med. Pediatr. Oncol. 19(2) , 126-8, (1991)]
Retroviral transfer of the human MDR1 gene confers resistance to bisantrene-specific hematotoxicity.
2014-04-29
[Clin. Cancer Res. 2(6) , 973-80, (1996)]
1990-08-01
[Invest. New Drugs 8(3) , 313-5, (1990)]
Bisantrene in relapsed and refractory acute myelogenous leukemia.
1993-02-01
[Leuk. Lymphoma 9(3) , 217-20, (1993)]